News | Pacemakers | November 11, 2015

Medtronic Micra TPS Meets Global Clinical Trial's Safety, Effectiveness Endpoints

Data demonstrate high implant success and reduced healthcare utilization

Medtronic, Micra TPS, Global Clinical Trial, results

Image courtesy of Medtronic

November 11, 2015 — Medtronic plc announced that the Medtronic Micra Transcatheter Pacing System (TPS) was successfully implanted in nearly all patients in the trial and met its safety and effectiveness endpoints with wide margins. These data, from the Medtronic Micra TPS Global Clinical Trial, were presented during a late-breaking special report session at the 2015 American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine.

"We are extremely pleased with the remarkably successful implant rates and safety profile of the Micra pacemaker, including the absence of device dislodgments. We are especially confident in these results because the trial included patients with serious comorbidities from 19 countries on five continents around the world," said Dwight Reynolds, M.D., trial principal investigator and regent's professor and chief of the Cardiovascular Section at the University of Oklahoma Health Sciences Center. "The Micra TPS not only met its trial endpoints, but also provided a significant reduction in healthcare utilization due to fewer major complications compared to conventional pacing systems, which is particularly important in an era of value-based healthcare."

In the Micra trial, 96 percent of patients (700 of 725; six-month Kaplan-Meier estimate) experienced no major complications, which is 51 percent fewer major complications than seen in patients with conventional pacing systems (hazard ratio: 0.49; 95 percent CI, 0.33 to 0.75; P=0.001). Major complications included cardiac injuries (1.6 percent), complications at the groin site (0.7 percent) and pacing issues (0.3 percent). Notably, there were no dislodgments, no systemic infections and very few (0.4 percent) system revisions (meaning extraction, repositioning or replacement). These low complication rates were achieved despite the inclusion of high-risk patients worldwide, including patients with chronic obstructive pulmonary disease (COPD).

The presentation included a comparison of Micra TPS safety performance to a pre-defined, historical control group consisting of more than 2,500 patients from six studies of commercially available, conventional pacing systems. Compared to patients with conventional systems, the patients in the Micra trial were older and had more comorbidities, yet had fewer major complications.

Almost all patients in the trial, 98.3 percent (292 of 297) had low and stable pacing thresholds at six months, yielding projected average longevity for the device of more than 12 years (300 patients at six months).

In addition, the low major complication rates experienced by Micra patients resulted in significant reductions in healthcare utilization compared to conventional pacing systems: Micra patients had 54 percent fewer hospitalizations (p=0.011) and 87 percent fewer system revisions (p<0.001) than observed in the historical control group.

At less than one-tenth the size of traditional pacemakers, the Micra TPS is the world's smallest pacemaker. It is cosmetically invisible and small enough to be delivered with minimally invasive techniques through a catheter, and implanted directly into the heart.

Comparable in size to a large vitamin, the Micra TPS does not require the use of leads to deliver pacing therapy; rather, its flexible tines attach to the interior of the right ventricle. The tines can be disengaged during the implant process without causing trauma to the cardiac tissue, allowing the device to be repositioned during implant and retrieved if needed. Micra TPS also is the first transcatheter pacing system to be awarded European CE Mark for 1.5T and 3T full body magnetic resonance imaging (MRI) scanning, providing patients with access to the most advanced imaging diagnostic procedures.

In the United States, the Micra TPS is an investigational device and not yet approved for commercial use. The device was awarded CE Mark in April 2015 based on earlier data from the Medtronic Micra TPS Global Clinical Trial.

The trial enrolled 744 patients; it is ongoing and will continue to evaluate the safety and efficacy of the device through a single-arm, multi-center study at 56 centers in 19 countries. Primary endpoints of the trial were freedom from device-related or procedure-related major complications with target performance of >90 percent (lower CI >83 percent) at six months, and low and stable pacing thresholds as demonstrated by <= 2V and no increase of >1.5V (relative to implant) and target performance of >89 percent (lower CI >80 percent) in the first 300 patients at six months.

For more information: www.medtronic.com

Related Content

A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Heart Rhythm 2019 study shows travelers with common cardiac devices can pass through without restrictions or precautions. HRS 2019, #HRS #HRS19

A new study shows travelers with common cardiac devices can pass through airport body scanners without restrictions or precautions.

News | EP Lab | May 14, 2019
May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), su
News | EP Lab | May 13, 2019
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their
Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Feature | EP Lab | March 22, 2019
March 22, 2019 — The U.S.
Medtronic Tyrx Envelope Significantly Reduces Major Infections in Cardiac Implantable Device Patients
News | EP Lab | March 20, 2019
Results from the landmark Worldwide Randomized Antibiotic Envelope Infection Prevention Trial (WRAP-IT) demonstrated...
Videos | EP Lab | February 27, 2019
This is a virtual heart with the same electrophysiology characteristics as the real patient being developed to help o
Seth Worley, M.D., senior consultant, section of cardiac electrophysiology, MedStar Heart and Vascular Institute, developed tools and techniques to optimize transvenous left ventricular (LV) lead implantation, including the I-CRT approach. Here he holds the tools that he personally developed for left ventricular lead implantation to treat heart failure. Photo courtesy of MedStar Heart and Vascular Institute at MedStar Washington Hospital Center.

Seth Worley, M.D., senior consultant, section of cardiac electrophysiology, MedStar Heart and Vascular Institute, developed tools and techniques to optimize transvenous left ventricular (LV) lead implantation, including the I-CRT approach. Here he holds the tools that he personally developed for left ventricular lead implantation to treat heart failure. Photo courtesy of MedStar Heart and Vascular Institute at MedStar Washington Hospital Center.

Feature | EP Lab | January 21, 2019 | Matthew S. McKillop, M.D., FACC, FHRS, and Seth J. Worley, M.D.
Interventional...
An implanted ICD showing its three venous leads. These multiple CRT leads can cause issues when they need to be replaced and are abandoned with new leads put over them in the SVC, which may require lead extraction.

An implanted ICD showing its three leads in the venous system. 

Feature | EP Lab | January 13, 2019 | Dave Fornell, Editor
To extract or abandon broken or infected implantable, venous...
Overlay Init